Amoy Diagnostics

Lung cancer remains the leading cause of cancer-related deaths globally, with advanced Non-Small Cell Lung Cancer (NSCLC) posing significant challenges due to delayed treatment and limited access to critical biomarker information. At AmoyDx, we stand united with the lung cancer community this November—and every day—committed to advancing diagnostic solutions that can truly transform patient outcomes. 🎯 Our AmoyDx® Pan Lung Cancer PCR Panel (PLC Panel) is a game-changer, delivering precise insights on 11 key biomarkers in just 1 day. This rapid turnaround empowers healthcare professionals to confidently make personalized, patient-centered treatment decisions, accelerating the path to care when every moment counts. 💡 Watch the video to discover how our PLC Panel is making a difference in the fight against lung cancer. 🌐 Learn more: https://lnkd.in/ggrkTT6V Together, let's drive awareness, innovation, and hope for those affected by lung cancer. #LungCancerAwarenessMonth #LungCancer #PrecisionOncology #NSCLC #AmoyDx #Diagnostic #BiomarkerTesting

✨ Excited to conclude an incredible experience at ESMO Asia Congress 2024! We were thrilled to connect with so many new and familiar faces, sharing ideas and creating opportunities to advance precision oncology. Cancer care is evolving, and we're proud to play a role in breaking barriers and expanding access to innovative solutions—ensuring no patient is left behind. If we missed you at the event, we’d love to continue the conversation. Learn more and reach out to us here: https://lnkd.in/gq69qRac Let’s keep building a future where precision oncology transforms lives! #ESMOAsia2024 #PrecisionOncology #CancerCare #Innovation

Exciting Research Update from ESMO Asia 2024! 🚨 We’re excited to share a pioneering study presented by our users, showcasing the pivotal role of the AmoyDx PLC Panel in enabling rapid, preoperative detection of key actionable genomic alterations (AGAs), guiding personalized treatment strategies for early-stage NSCLC. Conducted as part of the LC-SCRUM-Advantage/MRD multicenter genomic screening initiative in Japan, the study explores the frequency and characteristics of AGAs in early-stage NSCLC patients, emphasizing the critical role of precision diagnostics in perioperative care. Key findings include: ✅ 46% of patients harbored AGAs, with EGFR mutations, MET exon 14 skipping, and KRAS G12C being the most frequent alterations. ✅ AGAs were predominantly found in adenocarcinoma cases and non-smokers, highlighting the essential need for targeted therapies for these groups. 📍 Join us at Booth C405 to explore how the AmoyDx PLC Panel and our innovative solutions can accelerate your research and drive groundbreaking results. 🔗 Dive deeper into the study here: https://lnkd.in/gR2Q3kH6 #ESMOAsia2024 #AmoyDx #PrecisionMedicine #NSCLC #TargetedTherapy #LungCancer #PrecisionDiagnostics

A recent study revealed that Vinmec Hospital has successfully established Vietnam’s first centralized HRD testing laboratory, passing all registered EMQN schemes. This milestone is powered by the AmoyDx HRD Focus Panel and our expert support services. Using the AmoyDx HRD Focus Panel, the laboratory analyzed 289 samples from high-grade serous ovarian cancer patients and identified 174 samples with HRR pathway defects out of which 42 samples were detected with a likely pathogenic variant . These findings highlight the critical role of personalized medicine and cutting-edge diagnostics in transforming cancer care in Vietnam. 📖 Explore the full study here: https://lnkd.in/ghDpD_aj 📍 Join us at Booth C405 tomorrow during ESMO Asia 2024 to learn more about the HRD Focus assay and discover how AmoyDx is advancing cancer diagnostics and driving the future of precision oncology. #ESMOAsia2024 #OvarianCancer #AmoyDx #HRD #PrecisionMedicine #CancerCare #Oncology #Vietnam #PrecisionDiagnostics

🌟 This November has been an incredible journey for the AmoyDx team as we partnered with our trusted local distributors and esteemed Key Opinion Leaders (KOLs) at events across the globe. We extend our deepest gratitude to our distributors for their unwavering commitment and to the KOLs for generously sharing their expertise, guiding us toward a future where precision oncology is within reach for all. Together, we’re breaking barriers in healthcare and paving the way for better patient outcomes. Let’s continue this incredible momentum to drive even greater success in the months ahead! 🌍✨🔬 S.I.A.L srl, EXCILONE #PrecisionOncology #AmoyDx #event #Collaboration

We are excited to announce a new partnership with Cambridge Bioscience, a trusted UK-based distributor with over 30 years of experience in life science research and diagnostic products. This collaboration reinforces AmoyDx's commitment to bringing equal access to precision diagnostics worldwide. Through this partnership, our cutting-edge NGS solutions are now readily available to researchers and healthcare providers in the UK and Ireland. Together, we look forward to advancing scientific discovery and improving patient care across the region. 🌍🔬 #NewPartnership #PrecisionOncology #NGS #LifeSciences

We’ll attend the ESMO Asia 2024 in Singapore from December 6-8. 🎉 Catch us at booth #C405, where we’ll be showcasing our strategic NGS and PCR solutions designed to advance precision oncology and diagnostics. 🔍 Discover how our cutting-edge technologies are making a difference in cancer care across Asia and beyond. Don’t miss this opportunity to connect with our experts and learn how we can support your diagnostic needs! Schedule a 1:1 meeting with our team 👉 : https://lnkd.in/gV6W-hbK We look forward to seeing you there! #ESMOAsia2024 #PrecisionOncology #Cancer #AmoyDx

🌍 Cancer knows no boundaries, and access to precision oncology healthcare shouldn’t either. AmoyDx, in partnership with AstraZeneca, is transforming cancer care in Africa by expanding EGFR molecular testing for Non-Small Cell Lung Cancer (NSCLC)! Building on the success of #EGFR testing in Nigeria, we are now bringing this impactful initiative to Kenya. In collaboration with Moi Teaching and Referral Hospital, AmoyDx is introducing EGFR testing using the AmoyDx® EGFR 29 Mutations Detection Kit, ensuring accurate and timely diagnosis for lung cancer patients. 🤝 Together, we’re advancing access to EGFR-based targeted therapies and driving precision oncology across borders. Read the Astra Zeneca’s press release here👉: https://lnkd.in/gbfKeH2u For more details about the AmoyDx® EGFR 29 Mutations Detection Kit, visit👉: https://lnkd.in/gM5ky2pg #PrecisionMedicine #NSCLC #EGFRm #TargetedTherapy

🌟 Biliary tract cancer is a devastating disease with one of the poorest prognoses among cancers, second only to pancreatic cancer. With a 5-year survival rate of just 25%, this cancer has historically been characterized by a lack of effective drug therapies, leaving patients with limited options and significant unmet medical needs. The launch of TASFYGO® Tablets 35mg by Eisai marks a major breakthrough, providing patients with access to a highly targeted therapy and bringing renewed hope to those battling this challenging cancer. 🧬We are especially proud that the AmoyDx® FGFR2 Break-apart FISH Probe Kit by Nihon Stery, Inc. (Headquarters: Tokyo), was approved in August 2024 as the companion diagnostic for TASFYGO. This diagnostic tool enables precise detection of FGFR2 gene fusions or rearrangements, ensuring patients receive the most effective treatment. 🔗 Read Eisai’s full launch announcement: https://lnkd.in/gHHWJHDZ 🔗 For the latest updates on the AmoyDx® FGFR2 Break-apart FISH Probe Kit as a companion diagnostic, visit: https://lnkd.in/g_JBkzmB #AmoyDx #PrecisionOncology #CancerDiagnostics #FGFR2 #TASFYGO #Eisai #TargetedTherapies #CompanionDiagnostics

✨ AmoyDx 2024 Distributors Annual Meeting Recap ✨ We’re thrilled to have successfully hosted our 2024 Distributors Annual Meeting in Düsseldorf, Germany! 🎉 It was an inspiring day of insightful discussions and collaborative knowledge sharing, all focused on advancing oncology diagnostics and addressing the evolving needs of the industry. A special thank you to our distinguished guest speakers, Dr. Pantelis, Dr. Boris, and Jasmine Lee, for their expert contributions. 👏 AmoyDx remains dedicated to decentralised healthcare solutions, ensuring high-quality diagnostic tests are accessible to patients everywhere. As we look to 2025, we are excited to continue working with our global partners to drive progress in precision oncology. A big thank you to all our partners, speakers, and attendees for making this event a tremendous success. We look forward to building on our achievements and furthering our collaboration toward a brighter future in precision medicine! 🌍🔬 Read the full press release here: https://lnkd.in/gaegJkTV #AmoyDx #PrecisionOncology #Diagnostics #GlobalCollaboration #Healthcare